SynthesisFrontiers in pharmacology2025
A systematic review of progress toward unlocking the power of epigenetics in breast cancer: latest updates and perspectives.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Epigenetic Plasticity in Triple-Negative Breast Cancer: Mechanisms of Therapy Resistance, Biomarkers, and Therapeutic Vulnerabilities.Biomedicines · 2026Review
- Histone lactylation: a novel epigenetic bridge linking cellular metabolism to benign and malignant gynecological diseases.Clinical epigenetics · 2026Review
- Development and validation of an 11-CpG methylation signature-based nomogram for predicting prognosis in early-onset breast cancer.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is among the most prevalent malignancies globally. It is progressively acknowledged as a diverse type of cancer, exhibiting considerable differences in its genomic and transcriptomic characteristics. Its growing evidence highlights the substantial role of epigenetic modification in pathogenesis, prognosis and treatment. Cancer and epigenetics are closely linked; abnormal epigenetic changes can influence numerous aspects of cancer biology, including unusual transcription patterns, initiation of cancer, its progression, resistance to drugs, and metastasis. Epigenetic drugs (epi-drugs), including DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibitors, serve as promising therapeutic agents, particularly in combination with conventional therapies. Additionally, nanotechnology-assisted epi-drug delivery systems are emerging as innovative approaches to enhance treatment efficacy and reduce systemic toxicity. While several epigenetic biomarkers have shown potential in liquid and tissue biopsies, their clinical validation remains a challenge. The integration of epigenetic insights into personalized medicine could revolutionize BC management, offering more targeted and effective treatment strategies. This systematic review aims to evaluate recent advancement in epigenetic research related to BC, focusing on diagnostic and prognostic biomarkers, epigenetic-based therapies and ongoing clinical trials. A comprehensive literature search was carried out in databases like PubMed, Scopus, and Google Scholar up to January 2025, following PRISMA guidelines. Seventy two (72) studies were included, addressing key aspects of DNA methylation, histone modification, and non-coding RNAs as potential biomarkers for early detection and disease progression monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.